Genetics of Parkinson disease: paradigm shifts and future prospects (original) (raw)

• Tanner, C. M. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv. Neurol. 91, 133–142 (2003).
  PubMed Google Scholar
• Wirdefeldt, K., Gatz, M., Schalling, M. & Pedersen, N. L. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 63, 305–311 (2004).
  Article PubMed Google Scholar
• Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601–607 (2004). Describes the identification of the PARK8 gene, LRRK2 , as a cause of late-onset Parkinson disease that might be associated with a pleomorphic pathology.
  Article CAS PubMed Google Scholar
• Valente, E. M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158–1160 (2004).
  Article CAS PubMed Google Scholar
• Singleton, A. B. et al. α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003). Describes the discovery of α-synuclein multiplication mutations, which showed that simple overexpression of the wild-type protein is sufficient to cause disease. This work also suggests that Parkinson disease and dementia with Lewy bodies share the same aetiology.
  Article CAS PubMed Google Scholar
• Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045–2047 (1997).
  Article CAS PubMed Google Scholar
• Paisan-Ruiz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595–600 (2004).
  Article CAS PubMed Google Scholar
• Leroy, E. et al. The ubiquitin pathway in Parkinson's disease. Nature 395, 451–452 (1998).
  Article CAS PubMed Google Scholar
• Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605–608 (1998).
  Article CAS PubMed Google Scholar
• Bonifati, V. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256–259 (2003).
  Article CAS PubMed Google Scholar
• Maraganore, D. et al. High-resolution whole genome association study of Parkinson's disease. Am. J. Hum. Genet. 77, 685–693 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Fahn, S. Description of Parkinson's disease as a clinical syndrome. Ann. NY Acad. Sci. 991, 1–14 (2003). An excellent review of the clinical symptomatology of Parkinson disease.
  Article CAS PubMed Google Scholar
• Van Den Eeden, S. K. et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157, 1015–1022 (2003).
  Article PubMed Google Scholar
• Hughes, A. J., Daniel, S. E., Ben-Shlomo, Y. & Lees, A. J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125, 861–870 (2002).
  Article PubMed Google Scholar
• Chen, L. & Feany, M. B. α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nature Neurosci. 8, 657–663 (2005). Provides functional insights to suggest that α-synuclein inclusions and Lewy bodies might be protective rather than pathogenic.
  Article CAS PubMed Google Scholar
• Firestone, J. A. et al. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch. Neurol. 62, 91–95 (2005).
  Article PubMed Google Scholar
• Jankovic, J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology 64, 2021–2028 (2005).
  Article CAS PubMed Google Scholar
• Priyadarshi, A., Khuder, S. A., Schaub, E. A. & Priyadarshi, S. S. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ. Res. 86, 122–127 (2001).
  Article CAS PubMed Google Scholar
• Allam, M. F., Campbell, M. J., Hofman, A., Del Castillo, A. S. & Fernandez-Crehuet Navajas, R. Smoking and Parkinson's disease: systematic review of prospective studies. Mov. Disord. 19, 614–621 (2004).
  Article PubMed Google Scholar
• Leroux, P.-D. Contribution à l'Étude des Causes de la Paralysie Agitante. Thèse de Paris, Imprimeur de la Faculté de Médecine (1880) (in French).
  Google Scholar
• Allen, W. Inheritance of the shaking palsy. Arch. Int. Med. 60, 424–436 (1937).
  Article Google Scholar
• Mjones, H. Paralysis Agitans. A clinical and genetic study. Acta Psychiatr. Neurol. Scand. Supplement 54, 1–195 (Ejnar Munksgaard, Copenhagen, 1949).
• Piccini, P., Burn, D. J., Ceravolo, R., Maraganore, D. & Brooks, D. J. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann. Neurol. 45, 577–582 (1999).
  Article CAS PubMed Google Scholar
• Tanner, C. M. et al. Parkinson disease in twins: an etiologic study. JAMA 281, 341–346 (1999).
  Article CAS PubMed Google Scholar
• Sveinbjornsdottir, S. et al. Familial aggregation of Parkinson's disease in Iceland. N. Engl. J. Med. 343, 1765–1770 (2000).
  Article CAS PubMed Google Scholar
• Rocca, W. A. et al. Familial aggregation of Parkinson's disease: The Mayo Clinic family study. Ann. Neurol. 56, 495–502 (2004).
  Article PubMed Google Scholar
• Simon, D. K., Lin, M. T. & Pascual-Leone, A. 'Nature versus nurture' and incompletely penetrant mutations. J. Neurol. Neurosurg. Psychiatry 72, 686–689 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Valente, E. M. et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 56, 336–341 (2004).
  Article CAS PubMed Google Scholar
• Maraganore, D. M. et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann. Neurol. 55, 512–521 (2004).
  Article CAS PubMed Google Scholar
• Lotharius, J. & Brundin, P. Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nature Rev. Neurosci. 3, 932–942 (2002).
  Article CAS Google Scholar
• Sidhu, A., Wersinger, C., Moussa, C. E. & Vernier, P. The role of α-synuclein in both neuroprotection and neurodegeneration. Ann. NY Acad. Sci. 1035, 250–270 (2004).
  Article CAS PubMed Google Scholar
• Bostantjopoulou, S. et al. Clinical features of parkinsonian patients with the α-synuclein (G209A) mutation. Mov. Disord. 16, 1007–1013 (2001).
  Article CAS PubMed Google Scholar
• Kruger, R. et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Genet. 18, 106–108 (1998).
  Article CAS PubMed Google Scholar
• Zarranz, J. J. et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164–173 (2004).
  Article CAS PubMed Google Scholar
• Hope, A. & Farrer, M. in Molecular Mechanisms in Parkinson's Disease (eds Philipp, K. & Haass, C.) (Landes Bioscience, Georgetown, Texas, 2004).
  Google Scholar
• Lashuel, H. A. et al. α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089–1102 (2002).
  Article CAS PubMed Google Scholar
• Farrer, M. et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann. Neurol. 55, 174–179 (2004).
  Article CAS PubMed Google Scholar
• Chartier-Harlin, M. C. et al. α-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167–1169 (2004).
  Article CAS PubMed Google Scholar
• Ibanez, P. et al. Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169–1171 (2004).
  Article CAS PubMed Google Scholar
• Nishioka, K. et al. Clinical heterogeneity of α-synuclein gene duplication in autosomal dominant familial Parkinson's disease. Ann. Neurol. 59, 298–309 (2006).
  Article CAS PubMed Google Scholar
• Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469–6473 (1998).
  Article CAS PubMed Google Scholar
• McKeith, I. G. et al. Dementia with Lewy bodies. Semin. Clin. Neuropsychiatry 8, 46–57 (2003).
  Article PubMed Google Scholar
• Poewe, W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov. Disord. 20, S77–S82 (2005).
  Article PubMed Google Scholar
• Pals, P. et al. α-Synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol. 56, 591–595 (2004).
  Article CAS PubMed Google Scholar
• Mueller, J. C. et al. Multiple regions of α-synuclein are associated with Parkinson's disease. Ann. Neurol. 57, 535–541 (2005).
  Article CAS PubMed Google Scholar
• Chiba-Falek, O., Kowalak, J. A., Smulson, M. E. & Nussbaum, R. L. Regulation of α-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am. J. Hum. Genet. 76, 478–492 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Mellick, G. D., Maraganore, D. M. & Silburn, P. A. Australian data and meta-analysis lend support for α-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease. Neurosci. Lett. 375, 112–116 (2005).
  Article CAS PubMed Google Scholar
• Outeiro, T. F. & Lindquist, S. Yeast cells provide insight into α-synuclein biology and pathobiology. Science 302, 1772–1775 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Lakso, M. et al. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α-synuclein. J. Neurochem. 86, 165–172 (2003).
  Article CAS PubMed Google Scholar
• Fernagut, P. O. & Chesselet, M. F. α-Synuclein and transgenic mouse models. Neurobiol. Dis. 17, 123–130 (2004).
  Article CAS PubMed Google Scholar
• Yamada, M., Iwatsubo, T., Mizuno, Y. & Mochizuki, H. Overexpression of α-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J. Neurochem. 91, 451–461 (2004).
  Article CAS PubMed Google Scholar
• Perez, R. G. & Hastings, T. G. Could a loss of α-synuclein function put dopaminergic neurons at risk? J. Neurochem. 89, 1318–1324 (2004).
  Article CAS PubMed Google Scholar
• Feany, M. B. & Bender, W. W. A Drosophila model of Parkinson's disease. Nature 404, 394–398 (2000).
  Article CAS PubMed Google Scholar
• Takahashi, M. et al. Phosphorylation of α-synuclein characteristic of synucleinopathy lesions is recapitulated in αsynuclein transgenic Drosophila. Neurosci. Lett. 336, 155–158 (2003).
  Article CAS PubMed Google Scholar
• Auluck, P. K., Meulener, M. C. & Bonini, N. M. Mechanisms of suppression of α-synuclein neurotoxicity by geldanamycin in Drosophila. J. Biol. Chem. 280, 2873–2878 (2005).
  Article CAS PubMed Google Scholar
• Fujiwara, H. et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biol. 4, 160–164 (2002).
  Article CAS PubMed Google Scholar
• Nonaka, T., Iwatsubo, T. & Hasegawa, M. Ubiquitination of α-synuclein. Biochemistry 44, 361–368 (2005).
  Article CAS PubMed Google Scholar
• Funayama, M. et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1. Ann. Neurol. 51, 296–301 (2002).
  Article CAS PubMed Google Scholar
• Kachergus, J. et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76, 672–680 (2005). This work shows that a common founder was responsible for the most frequent mutation to cause Parkinson disease that has been identified so far: LRRK2 Gly2019Ser. It also provides an age-associated penetrance estimate.
  Article CAS PubMed PubMed Central Google Scholar
• Paisan-Ruiz, C. et al. Familial Parkinson's disease: clinical and genetic analysis of four Basque families. Ann. Neurol. 57, 365–372 (2005).
  Article PubMed Google Scholar
• Funayama, M. et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 57, 918–921 (2005).
  Article CAS PubMed Google Scholar
• Mata, I. F. et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6, 171–177 (2005).
  Article CAS PubMed Google Scholar
• Gilks, W. P. et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365, 415–416 (2005).
  CAS PubMed Google Scholar
• Di Fonzo, A. et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365, 412–415 (2005).
  Article CAS PubMed Google Scholar
• Nichols, W. C. et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365, 410–412 (2005).
  CAS PubMed Google Scholar
• Farrer, M. et al. LRRK2 mutations in Parkinson disease. Neurology 65, 738–740 (2005).
  Article CAS PubMed Google Scholar
• Tomiyama, H. et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 different countries. Mov. Disord. 2006 (doi: 10.1002/mds.20886).
• Ozelius, L. J. et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354, 424–425 (2006).
  Article CAS PubMed Google Scholar
• Lesage, S. et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354, 422–423 (2006).
  Article CAS PubMed Google Scholar
• Lesage, S. et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann. Neurol. 58, 784–787 (2005).
  Article CAS PubMed Google Scholar
• Aasly, J. O. et al. Clinical features of _LRRK2_-associated Parkinson's disease in central Norway. Ann. Neurol. 57, 762–765 (2005).
  Article CAS PubMed Google Scholar
• West, A. B. et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA 102, 16842–16847 (2005).
  Article CAS PubMed Google Scholar
• Gloeckner, C. J. et al. The Parkinson disease causing LRRK2 mutation I20202T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223–232 (2006). References 72 and 73 show that LRRK2 substitutions might enhance kinase activity, which indicates the therapeutic possibility of kinase inhibition as a neuroprotective therapy in Parkinson disease.
  Article CAS PubMed Google Scholar
• Ross, O. A. et al. Lrrk2 and Lewy body disease. Ann. Neurol. 59, 388–393 (2006).
  Article CAS PubMed Google Scholar
• Wszolek, Z. K. et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62, 1619–1622 (2004).
  Article CAS PubMed Google Scholar
• Hasegawa, K. & Kowa, H. Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy. Eur. Neurol. 38, 39–43 (1997).
  Article CAS PubMed Google Scholar
• Giasson, B. I. et al. Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59, 315–322 (2005).
  Article CAS Google Scholar
• Bosgraaf, L. et al. A novel cGMP signalling pathway mediating myosin phosphorylation and chemotaxis in Dictyostelium. EMBO J. 21, 4560–4570 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Katzenschlager, R. & Lees, A. J. Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr. Opin. Neurol. 17, 417–423 (2004).
  Article PubMed Google Scholar
• Meylan, E. & Tschopp, J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem. Sci. 30, 151–159 (2005).
  Article CAS PubMed Google Scholar
• Mata, I. F., Lockhart, P. J. & Farrer, M. J. Parkin genetics: one model for Parkinson's disease. Hum. Mol. Genet. 13, R127–R133 (2004).
  Article CAS PubMed Google Scholar
• Abou-Sleiman, P. M., Healy, D. G. & Wood, N. W. Causes of Parkinson's disease: genetics of DJ-1. Cell Tissue Res 318, 185–188 (2004).
  Article CAS PubMed Google Scholar
• Shimura, H. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin–protein ligase. Nature Genet. 25, 302–305 (2000). Functional insights from the first gene to be implicated in early-onset parkinsonism, Parkin, highlighted the role of the ubiquitin–proteasome pathway in pure nigral neuronal degeneration.
  Article CAS PubMed Google Scholar
• Pramstaller, P. P. et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann. Neurol. 58, 411–422 (2005).
  Article CAS PubMed Google Scholar
• Sriram, S. R. et al. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. Genet. 14, 2571–2586 (2005).
  Article CAS PubMed Google Scholar
• Betarbet, R., Sherer, T. B. & Greenamyre, J. T. Ubiquitin–proteasome system and Parkinson's diseases. Exp. Neurol. 191, S17–S27 (2005).
  Article CAS PubMed Google Scholar
• Kahle, P. J. & Haass, C. How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep. 5, 681–685 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Ko, H. S. et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci. 25, 7968–7978 (2005).
  Article CAS PubMed Google Scholar
• Lo Bianco, C. et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease. Proc. Natl Acad. Sci. USA 101, 17510–17515 (2004).
  Article CAS PubMed Google Scholar
• Greene, J. C., Whitworth, A. J., Andrews, L. A., Parker, T. J. & Pallanck, L. J. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum. Mol. Genet. 14, 799–811 (2005).
  Article CAS PubMed Google Scholar
• Valente, E. M. et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35–p36. Am. J. Hum. Genet. 68, 895–900 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Hatano, Y. et al. Novel PINK1 mutations in early-onset parkinsonism. Ann. Neurol. 56, 424–427 (2004).
  Article CAS PubMed Google Scholar
• Petit, A. et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson's disease-related mutations. J. Biol. Chem. 280, 34025–34032 (2005).
  Article CAS PubMed Google Scholar
• Beilina, A. et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl Acad. Sci. USA 102, 5703–5708 (2005).
  Article CAS PubMed Google Scholar
• Deng, H., Jankovic, J., Guo, Y., Xie, W. & Le, W. Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun. 337, 1133–1138 (2005).
  Article CAS PubMed Google Scholar
• Kessler, K. R. et al. Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome. J. Neural Transm. 112, 1345–1353 (2005).
  Article CAS PubMed Google Scholar
• Khan, N. L. et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann. Neurol. 52, 849–853 (2002).
  Article PubMed Google Scholar
• Lockhart, P. J. et al. DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J. Med. Genet. 41, e22 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Tao, X. & Tong, L. Crystal structure of human DJ-1, a protein associated with early onset Parkinson's disease. J. Biol. Chem. 278, 31372–31379 (2003).
  Article CAS PubMed Google Scholar
• Zhang, L. et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet. 14, 2063–2073 (2005).
  Article CAS PubMed Google Scholar
• Goldberg, M. S. et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45, 489–496 (2005).
  Article CAS PubMed Google Scholar
• Kim, R. H. et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl Acad. Sci. USA 102, 5215–5220 (2005).
  Article CAS PubMed Google Scholar
• Yang, Y. et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc. Natl Acad. Sci. USA 102, 13670–13675 (2005).
  Article CAS PubMed Google Scholar
• Meulener, M. et al. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr. Biol. 15, 1572–1577 (2005).
  Article CAS PubMed Google Scholar
• Dekker, M. C. et al. PET neuroimaging and mutations in the DJ-1 gene. J. Neural Transm. 111, 1575–1581 (2004).
  Article CAS PubMed Google Scholar
• Rizzu, P. et al. DJ-1 colocalizes with tau inclusions:a link between parkinsonism and dementia. Ann. Neurol. 55, 113–118 (2004).
  Article CAS PubMed Google Scholar
• Scott, W. K. et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 286, 2239–2244 (2001).
  Article CAS PubMed Google Scholar
• Hicks, A. A. et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. Neurol. 52, 549–555 (2002).
  Article CAS PubMed Google Scholar
• DeStefano, A. L. et al. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am. J. Hum. Genet. 70, 1089–1095 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Li, Y. J. et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am. J. Hum. Genet. 70, 985–993 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Pankratz, N. et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum. Mol. Genet. 12, 2599–2608 (2003).
  Article CAS PubMed Google Scholar
• Martinez, M. et al. Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease. J. Med. Genet. 41, 900–907 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Hutton, M. Molecular genetics of chromosome 17 tauopathies. Ann. NY Acad. Sci. 920, 63–73 (2000).
  Article CAS PubMed Google Scholar
• Skipper, L. et al. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am. J. Hum. Genet. 75, 669–677 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Rademakers, R. et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum. Mol. Genet. 14, 3281–3292 (2005).
  Article CAS PubMed Google Scholar
• Liu, Y., Fallon, L., Lashuel, H. A., Liu, Z. & Lansbury, P. T. Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209–218 (2002).
  Article CAS PubMed Google Scholar
• Shen, J. & Cookson, M. R. Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron 43, 301–304 (2004).
  Article CAS PubMed Google Scholar
• Uitti, R. J., Calne, D. B., Dickson, D. W. & Wszolek, Z. K. Is the neuropathological 'gold standard' diagnosis dead? Implications of clinicopathological findings in an autosomal dominant neurodegenerative disorder. Parkinsonism Relat. Disord. 10, 461–463 (2004).
  Article PubMed Google Scholar
• Forman, M. S., Lee, V. M. & Trojanowski, J. Q. Nosology of Parkinson's disease: looking for the way out of a quackmire. Neuron 47, 479–482 (2005).
  Article CAS PubMed Google Scholar
• Trojanowski, J. Q. & Lee, V. M. Transgenic models of tauopathies and synucleinopathies. Brain Pathol. 9, 733–739 (1999).
  Article CAS PubMed Google Scholar
• Parkkinen, L., Kauppinen, T., Pirttila, T., Autere, J. M. & Alafuzoff, I. α-Synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann. Neurol. 57, 82–91 (2005).
  Article CAS PubMed Google Scholar
• Wittmann, C. W. et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711–714 (2001).
  Article CAS PubMed Google Scholar
• Santacruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476–481 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Olanow, C. W. et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov. Disord. 19, 997–1005 (2004).
  Article PubMed Google Scholar
• Fahn, S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47, S2–S9; discussion S9–S11 (2000).
  Article CAS PubMed Google Scholar
• Walter, B. L. & Vitek, J. L. Surgical treatment for Parkinson's disease. Lancet Neurol. 3, 719–728 (2004).
  Article PubMed Google Scholar
• Masliah, E. et al. Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857–868 (2005). A demonstration of the power of genetic insights in nominating targets for translational advances and creating the models in which to test them.
  Article CAS PubMed Google Scholar
• Ross, O. A. & Farrer, M. J. Pathophysiology, pleiotrophy and paradigm shifts: genetic lessons from Parkinson's disease. Biochem. Soc. Trans. 33, 586–590 (2005).
  Article CAS PubMed Google Scholar
• Silva, R. M., Kuan, C. Y., Rakic, P. & Burke, R. E. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. Mov. Disord. 20, 653–664 (2005).
  Article PubMed Google Scholar
• Langston, J. W., Ballard, P., Tetrud, J. W. & Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979–980 (1983).
  Article CAS PubMed Google Scholar
• Hirsch, E. C. et al. Animal models of Parkinson's disease in rodents induced by toxins: an update. J. Neural Transm. Suppl. 65, 89–100 (2003).
  Article Google Scholar
• Hirano, A., Kurland, L. T., Krooth, R. S. & Lessell, S. Parkinsonism-dementia complex, an endemic disease on the island of Guam. I. Clinical features. Brain 84, 642–661 (1961).
  Article CAS PubMed Google Scholar
• Ince, P. G. & Codd, G. A. Return of the cycad hypothesis — does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health? Neuropathol. Appl. Neurobiol. 31, 345–353 (2005).
  Article CAS PubMed Google Scholar
• Hof, P. R. et al. Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders. Acta Neuropathol. (Berl.) 88, 397–404 (1994).
  Article CAS Google Scholar
• Sebeo, J., Hof, P. R. & Perl, D. P. Occurrence of α-synuclein pathology in the cerebellum of Guamanian patients with parkinsonism-dementia complex. Acta Neuropathol. (Berl.) 107, 497–503 (2004).
  Article CAS Google Scholar
• Caparros-Lefebvre, D. et al. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 125, 801–811 (2002).
  Article PubMed Google Scholar
• Economo Von, C. Encephalytis Lethargica: its Sequelae and Treatment (Oxford University Press, London, 1931).
  Google Scholar
• Dale, R. C. et al. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain 127, 21–33 (2004).
  Article PubMed Google Scholar
• Josephs, K. A., Parisi, J. E. & Dickson, D. W. α-Synuclein studies are negative in postencephalic parkinsonism of von Economo. Neurology 59, 645–646 (2002).
  Article PubMed Google Scholar
• Henry, J. M. & Jellinger, K. in Neurodegeneration: The molecular pathology of dementia and movement disorders (ed. Dickson, D.) (ISN Neuropath Press, Basel, 2003).
  Google Scholar